Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Tinengotinib Elicits Clinical Benefit in Pretreated Cholangiocarcinoma and Other Advanced Solid Tumors

July 24th 2023

Sanjay Goel, MD, MS, expands on the findings from the phase 1b/2 trial, noting the potential benefit this approach may have for patients with cholangiocarcinoma, and detailed next steps for investigating tinengotinib.

Regional Nodal Irradiation Has Minimal Effect on Locoregional Recurrence in Favorable-Risk, Node-Positive Breast Cancer

July 23rd 2023

Locoregional recurrence rates among patients with favorable-risk, node-positive hormone receptor-positive, HER2-negative breast cancer was not significantly reduced by the addition of regional nodal irradiation to these patient’s treatment regimens.

ASCP’s Outstanding Education Initiatives Receive Prestigious Awards

July 21st 2023

Two innovative ASCP education initiatives have received accolades from the Alliance for Continuing Education in the Health Professions.

Dr Krop on Age-Related Survival Outcomes With T-DXd in HER2+ Breast Cancer

July 21st 2023

Ian E. Krop, MD, PhD, discusses the use of fam-trastuzumab deruxtecan-nxki across age groups in the DESTINY Breast trials in patients with HER2-positive metastatic breast cancer.

Use of ADCs in the Second-Line Treatment of HER2+ mBC

July 20th 2023

Experts introduce the antibody-drug conjugates (ADCs) trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd) and discuss clinical trial findings and potential use in special patient populations, such as those with brain metastases.

Implementing Trial Data to Our Practice

July 20th 2023

Stephanie Graff, MD, and Rachel Layman, MD, discuss how they would apply the results of the monarchE trial to clinical case scenarios.

Standard-of-Care and Emerging Therapies for First-line Treatment of HER2+ mBC

July 20th 2023

Drs McArthur and Kaklamani expand upon the standard-of care regimens used for first-line treatment of patients with HER2+ metastatic breast cancer (mBC), review clinical data supporting their use, and share excitement for upcoming data readouts on novel regimens in the space.

Dosing CDK 4/6 Inhibitors

July 20th 2023

Rachel Layman, MD, summarizes how to dose CDK4/6 inhibitors in different clinical settings.

Unmet Needs and Clinical Pearls in the Treatment of HER2+ mBC

July 20th 2023

Megan Kruse, MD, offers advice to community oncologists treating HER2+ metastatic breast cancer and discusses unmet needs in the treatment landscape.

Breast Cancer Management: Future Directions in Fertility Preservation

July 19th 2023

Closing out their discussion on fertility preservation in breast cancer, Matteo Lambertini, MD, PhD, and Virginia Kaklamani, MD, DSc, look toward unmet needs and future evolutions in the treatment landscape and offer advice for community physicians.

Timing Fertility Preservation in Patients With Breast Cancer Undergoing Surgery

July 19th 2023

Expert oncologists Matteo Lambertini, MD, PhD, and Virginia Kaklamani, MD, DSc, review fertility preservation strategies in the context of patients with breast cancer undergoing surgery.

CDK4/6 Inhibitors in the Metastatic Breast Cancer Setting

July 18th 2023

The expert panel reviews CDK4/6 inhibitor options in the HR+/HER2- metastatic breast cancer (mBC) setting and previous data supporting their use.

Treatment and Dose Optimization in HR+/HER2- Early Breast Cancer

July 18th 2023

A comprehensive discussion on approaches to optimizing treatment selection and dosing in HR+/HER2- breast cancer.

Dr Tarantino on the Expansion of Treatment Options Post-CDK4/6 Inhibition in HR+ Breast Cancer

July 17th 2023

Paolo Tarantino, MD, discusses the expansion and selection of effective treatment options for patients with hormone receptor-positive breast cancer who progressed on a CDK 4/6 inhibitor.

Dr Sammons on the SONIA Trial of First-Line CDK4/6 Inhibitor Use in HR+/HER2– Breast Cancer

July 14th 2023

Sarah Sammons, MD, discusses whether CDK4/6 inhibitors should be considered a standard first line treatment within hormone receptor–positive, HER2-negative advanced breast cancer according to primary results from the phase 3 SONIA trial.

Age-Dependent Results With CDK 4/6 Inhibitors

July 13th 2023

Experts in breast oncology review age-dependent outcomes with CDK 4/6 inhibitors.

Data Updates and Ongoing Trials in the HER2+ Adjuvant Space

July 13th 2023

Panelists discuss recent data updates on standard-of-care and emerging regimens for adjuvant treatment of HER2+ eBC, including data presented at the 2023 ASCO meeting, and highlight exciting trials in progress that have not yet read out.

Ongoing Research in HER2+ Metastatic Breast Cancer

July 13th 2023

An overview of agents and treatment strategies currently being investigated in HER2+ metastatic breast cancer.

Individualizing Care with CDK 4/6 Inhibitors

July 13th 2023

Stephanie Graff, MD, and Rachel Layman, MD, discuss how to individualize care with CDK4/6 inhibitors in patients with high-risk early breast cancer.

HER2CLIMB-02: Tucatinib and T-DM1 in HER2+ Breast Cancer

July 13th 2023

Megan Kruse, MD, discusses the HER2CLIMB-02 study and the impact it may have on the HER2+ metastatic breast cancer treatment landscape.